The writer is a science commentator
What a difference a month makes. In February, scientists reported that an experimental vaccine showed promise in a small group of patients with pancreatic cancer, a disease that is often diagnosed late and carries a notoriously poor prognosis.
The vaccine — using messenger RNA (mRNA) technology similar to that found in some Covid vaccines — activated tumour-targeting immune cells that persisted for nearly four years after surgery in some patients. Not all 16 recipients produced an immune response but those who did were less likely to see their cancer recur. These early findings, from the Memorial Sloan Kettering Cancer Center in New York, have already spurred a follow-up study.
您已阅读16%（720字），剩余84%（3869字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。